With CBD, Marijuana-Based Medicine Gets its First Greenlight From the FDA
By Taylor Hatmaker
In a news release today, the FDA announced its approval of a marijuana-derived drug called Epidiolex for the treatment of seizures in a subset of patients suffering from severe epilepsy. Epidiolex contains CBD, a cannabis chemical compound skyrocketing in popularity and driving what is estimated to have doubled into a $200 million market in 2018.
CBD is the common abbreviation for cannabidiol, a chemical derived from cannabis. In contrast to THC, the far more popular cannabinoid CBD does not produce strong psychoactive effects when consumed. The chemical’s use in seizure prevention is well-documented in reputable research, and now, after conducting its own trials, the FDA is on board.
To read more: https://techcrunch.com/2018/06/25/what-is-cbd-fda/amp/